Tanya Singh

Daraxonrasib and the heart: cardiovascular implications of the first clinically successful pan-RAS(ON) inhibitor

Daraxonrasib (RMC-6236), the first orally bioavailable pan-RAS(ON) inhibitor, produced a significant survival benefit in the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), reducing the risk of death by 60% versus chemotherapy...